IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Core Insights - IGC Pharma, Inc. has entered into a Subscription Agreement for the sale of 779,997 shares of common stock at a price of $0.30 per share, expecting gross proceeds of approximately $234,000 [1][3] Group 1: Financing and Investment - The financing will support disciplined clinical execution and value creation in the development of Alzheimer's drugs [1] - The company welcomes sophisticated, long-term investors who bring not only capital but also experience and networks to support growth [2] Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital and general corporate purposes, including funding the Phase 2 clinical development program for IGC-AD1 [3] Group 3: Company Overview - IGC Pharma is a clinical-stage biotechnology company utilizing AI to develop treatments for Alzheimer's and metabolic disorders, with its lead asset IGC-AD1 currently in a Phase 2 trial [5] - The company's pipeline includes TGR-63 targeting amyloid plaques and early-stage programs focused on neurodegeneration and metabolic dysfunctions [5]